Theraly is a preclinical stage company that applies a novel, proprietary technology platform to create new drugs and improve existing drugs. Theraly aims to preserve the potency of peptides and small proteins while increasing their circulating half-lives.

Carradora Health, Inc. is a woman-owned small business dedicated to serving customers in healthcare information technology solutions in both the government and commercial spaces.  Our team has an exceptional background in providing personal service and innovative solutions on a variety of projects in Healthcare IT.

Current and recent projects for government clients center on research and development to enable the interoperability of electronic health records.  These efforts include subject areas such as testing and piloting patient-reported outcomes (PRO), developing long-term electronic services and supports, and improved standards around the Prescription Drug Monitoring Program (PDMP).

The expertise we provide covers a wide range of program support, including: working with standards development organizations (SDOs) to develop standards from PSS through to balloting and publishing, managing pilots with commercial and academic centers, convening in-person and on-line meetings of SMEs and other ranging from tens to hundreds of participants, healthcare IT vocabulary support.

Our team is committed to the advancement of Healthcare IT, and EHR interoperability in particular, in order to deliver better care to patients.

AcouSort is a Swedish company setting up a US presence. The company has a novel technology that uses acoustic fields to separate cells and particles to perform operations that is normally done by centrifugation in the biology or clinical lab.

The Fusion of Technology and Genomics.

NuSep is a Life Sciences company that provides innovative tools that speed up and simplify protein separation, fractionation, and proteomic analysis. We also developing a novel clinical diagnostic platform to improve health outcomes.

BiOneCure Therapeutics LLC is a biotechnology company committed to the discovery and development of innovative biotherapeutics for the treatment of cancer. The company is developing novel bispecific antibodies and a new class of antibody-drug conjugates (ADCs). Bispecific antibodies combine specificities of two different antibodies and are able to target two different antigens or epitopes simultaneously. ADCs are tumor-targeting antibodies chemically conjugated to a highly potent cytotoxic agent (warheads). Bispecific antibodies and ADCs promise huge potential for cancer therapy. A series of novel cytotoxic warheads being developed by BiOneCure feature new mechanisms of action for tumor cell killing and inhibition, which will enhance the therapeutic application and the safety of ADCs in clinical treatment of cancer patients. The company was founded in 2016 by industrial veterans and is based in Germantown, Maryland.